Published in Am Heart J on February 02, 2011
The role of triglycerides in atherosclerosis. Curr Cardiol Rep (2011) 1.38
How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep (2013) 1.20
The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord (2012) 0.98
Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: a multicenter reproducibility study. Int J Cardiovasc Imaging (2014) 0.95
Therapeutic strategies to deplete macrophages in atherosclerotic plaques. Br J Clin Pharmacol (2012) 0.88
Clinical factors associated with high-risk carotid plaque features as assessed by magnetic resonance imaging in patients with established vascular disease (from the AIM-HIGH Study). Am J Cardiol (2014) 0.88
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. Vasc Health Risk Manag (2012) 0.85
Exercise and dietary-mediated reductions in postprandial lipemia. J Nutr Metab (2014) 0.80
Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. Am J Med (2016) 0.79
Carotid Plaque Lipid Content and Fibrous Cap Status Predict Systemic CV Outcomes: The MRI Substudy in AIM-HIGH. JACC Cardiovasc Imaging (2017) 0.79
Pharmacotherapy: Implications of high-dose statin link with incident diabetes. Nat Rev Cardiol (2011) 0.78
The COSEHC™ Global Vascular Risk Management quality improvement program: first follow-up report. Vasc Health Risk Manag (2013) 0.77
Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct? Curr Atheroscler Rep (2015) 0.75
Strategies for improving cardiovascular health in women with diabetes mellitus: a review of the evidence. Curr Diab Rep (2015) 0.75
Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol (2017) 0.75
Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. Curr Diab Rep (2017) 0.75
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med (1987) 13.50
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 9.97
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med (1999) 9.83
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol (1986) 6.27
Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39
High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis (1996) 2.70
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA (1990) 2.36
Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol (1988) 2.22
Mechanism of action of niacin. Am J Cardiol (2008) 1.55
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin (2006) 1.53
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol (2010) 1.36
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther (2010) 1.18
Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am J Cardiol (2008) 0.87
Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Circulation (1993) 0.82